The nose knows the way toward protecting us from Covid-19, say leaders of a small Peninsula company hoping to start a clinical trial early next year for a vaccine against the potentially deadly coronavirus that has infected more than 10 million people globally.
Meissa Vaccines Inc., launched six years ago by former Emory University researcher Marty Moore and former MedImmune scientist Roderick Tang, said its vaccine delivered into the nose by droplets or spray offers one of the best opportunities to stop the virus known as SARS-CoV-2.
Read the full article in San Francisco Business Times (subscription may be required).